^
Association details:
| Biomarker: | TNFA-L |
|---|---|
| Cancer: | Melanoma |
| Drug: | Puyouheng (pucotenlimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
Published date:
02/06/2023
Excerpt:
Pucotenlimab as a ≥ 2nd line therapy showed promising efficacy and tolerable toxicity for patients with locally advanced or metastatic melanoma….We found that the levels of Eotaxin (CCL11) and MCP-1 (CCL2) were significantly higher when patients were at PR status compared to those at PD (iuPD/icPD) status. On the contrary, the levels of TNF-α and VEGF were significantly lower when patients were at PR status compared to those at PD status (as shown in Fig. 3).
DOI:
10.1186/s12885-022-10473-y
Trial ID:
